lg 100268 has been researched along with Angiogenesis, Pathologic in 1 studies
LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liby, K | 1 |
| Risingsong, R | 1 |
| Royce, DB | 1 |
| Williams, CR | 1 |
| Yore, MM | 1 |
| Honda, T | 1 |
| Gribble, GW | 1 |
| Lamph, WW | 1 |
| Vannini, N | 1 |
| Sogno, I | 1 |
| Albini, A | 1 |
| Sporn, MB | 1 |
1 other study available for lg 100268 and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2008 |